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The present study was designed to test the effect 
of pravastatin, a new, 9hydroxy+methylglutaryl 
coenzyme A reductase inhibitor, on the progres- 
sion of coronary artery disease in patients with 
moderate hypercholesterolemia. Angiographic eb 
try criteria included the presence of 21 stenosis 
250% in a major epicardial coronary artery, and 
certiication of film quality through the core an@- 
ography laboratory. Patients qualified for random 
ixation if after diet stabilization their low density 
lipoprotein cholesterol concentrations were 2130 
and cl90 mg/dl, and triglycerides were 1350 
mg/dl. Pravastatin (40 mg) or placebo is adminis 
tered once daily at bedtime. Arteriography will be 
repeated at the end of 3 years of treatment. The 
primary end point of the study is the change in * 
solute mean coronary artery diameter. During a 
99month recruitment period, 44,145 patients 
were screened, and 408 were randomized. The 
most frequent reason for excludi* patients dulc 
ing the screenhtg and dietary lea&in periods was 
a low senun cholesterol level. A large proportion 
of patients with documented coronary artery di+ 
ease have cholesterol concentrations that are 
considered to be normal or only modestly iu 
creased. Adherence to strict standards of quality 
control for di@tal analysis of angiograms ensures 
that baseline anfgograms can be interpreted at 
the end of Syear follow-up. 
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avastatin Limitation of Atherosclerosis in the Cor- P onary Arteries (PLAC I) is a multicenter, pro- spective, randomized, placebo-controlled trial of 
the effect of lipid-altering therapy on the progression of 
coronary artery disease. The study was designed with 2 
goals: The lirst was to evaluate the effects of monother- 
apy with pravastatin, a hydrophilic 3-hydroxy-3-meth- 
ylglutaryl coenzyme A reductase inhibitor, on progres- 
sion and regression of coronary artery disease measured 
by quantitative angiography. The second goal was to 
evaluate progression and regression of atherosclerosis in 
patients with only moderate increases of low-density li- 
poprotein (LDL) cholesterol, typical of those with symp- 
tomatic coronary artery disease. This article describes 
the protocol design and recruiting experience. 
METHODS 
The protocol was approved by the institutional re- 
view board at each study site. All patients gave written, 
informed consent to participate in the trial. The study 
was initiated in early 1988, and randomization ended 
after a 30-month recruitment period. All follow-up an- 
giography will be completed in the spring of 1993. 
5creening an@ography: At each site (see Appen- 
dix), all patients undergoing clinically indicated coro- 
nary arteriography were screened for eligibility. The pro- 
tocol for angiography required 22 orthogonal or near- 
orthogonal views of all coronary segments, central 
placement of the catheter (>5Fr) in the radiographic 
image, administration of nitroglycerin before injection of 
contrast medium (in the absence of contraindications), 
and detailed documentation of the sequence of injections 
during the procedure, including the angles of view. 
A patient had to have 21 stenosis 250% in a major 
epicardial coronary artery to qualify for the study. The 
protocol required review of the documentation of the 
procedure, presence of an adequate portion of the angio- 
graphic catheter in a central portion of the image, digi- 
tization of eligible angiographic segments, and exclusion 
of excessive contrast streaming. A previously described 
and validated quantitative coronary artery evaluation 
method was used to analyze all focal stenoses in any 
study segment. l 
Dietary stabilization/qualiication for randomizk+ 
tion: Patients who fulfilled the initial screening criteria 
were referred to a dietitian for instruction in a fat-re- 
stricted, low-cholesterol diet (American Heart Associa- 
PRAVASTATIN ATHEROSCLEROSIS TUDY DESIGN 31 
TABLE I Protocol Exclusion Criteria 
1. Life-threatening illnesses other than coronary artery disease with 
expected survival <3 years 
2. Premenopausal women of childbearing potential 
2. Age > 75 years 
3. Secondary causes for increased low-density lipoprotein cholesterol 
4. Diabetes mellitus (fasting blood sugar > 140 mg/dl, or needing 
treatment with insulin or oral hypoglycemic agents) 
5. Congestive heart failure with ejection fraction <30% 
6. Significant hepatic disease (alanine or aspartate aminotransferase, 
total bilirubin or alkaline phosphatase greater than upper limit of 
normal) 
7. Significant renal disease (creatinine >2.5 mg/dl, urinary protein 
>2+, and serum albumin <3 g/dl) 
8. Blood pressure > 160 mm Hg (systolic) or > 100 mm Hg (diastolic) 
despite treatment, or untreated 
9. History of cerebrovascular disease 
10. Gastrointestinal disease or surgery that may interfere with drug ab- 
sorption 
11. Alcohol consumption >3 drinks/day (1 drink = 1.5 oz of 80 proof 
liquor,‘or equivalent) 
12. Chronic pancreatitis 
13. History of hypersensitivity to 3-hydroxy-3-methylglutaryl coenzyme 
A reductase inhibitors 
14. Systemic lupus erythematosus 
tion Phase I or equivalent*). After 24 weeks of a stable 
diet, the lirst lipid prosle was determined; subsequent 
determinations were obtained at l- to 4-week intervals. 
To qualify for randomization, the average of 2 consecu- 
tive LDL cholesterol concentrations needed to be 2130 
mg/dl (3.36 mmol/liter) but <190 mg/dl (4.91 mmol/ 
liter), and the average triglycerides 13.50 mg/dl (3.95 
mmol/liter). 
Other inclusion/exclusion criteria: Before enroll- 
ment in the study, patients had to consent to coronary 
arteriography again at the end of 3 years of treatment. 
Patients receiving treatment with lipid-lowering therapy 
could be enrolled if an appropriate drug washout period 
preceded the t&t qualifying lipid determination. Other 
exclusion criteria are listed in Table I. 
Dtug m and Z&W&WOE Pravastatin or match- 
ing placebo (provided by the Bristol-Myers Squibb 
Pharmaceutical Research Institute) is administered as 
two 20 mg tablets at bedtime (40 mg total), and dosage 
remains lixed for the duration of the study unless safe- 
ty considerations dictate a reduction. Assignment to 
placebo or active drug is balanced witbin strata defined 
by clinical characteristics (myocardial infarction, percu- 
taneous transluminal coronary angioplasty and stable or 
unstable angina) and baseline LDL cholesterol concen- 
tration (130 to 169 and 170 to 189 mg/dl). 
Over the course of a 3-year study, LDL cholesterol 
may be expected to increase to 2190 mg/dl, approxi- 
mately the 90th percentile for the United States popula- 
tion in some patients. Because of the demonstrated ben- 
efits of treating patients with such marked cholesterol 
increase,3 care was taken to identify and treat them. If 
the mean of 3 consecutive LDL cholesterol levels is 
2190 mg/dl in any patient, personnel at the site are to 
be notified in writing to advance the diet to the Ameri- 
can Heart Association Phase II or equivalent diet.* To 
maintain study integrity and blinding, a patient from the 
other treatment group matched by age, sex and upper 
tertile of LDL cholesterol concentration is to be chosen 
to change diet also. If LDL cholesterol does not decrease 
to ~190 mgJll after 1 month, the patient and matching 
subject are to be instructed to begin taking cholestyra- 
mine resin beginning with 1 packet (bid) titrated to a 
maximum of 6 packets/day. Patients whose levels 
remain 2290 mg/dl despite addition of cholestyramine 
are to be administered 5 to 10 mg of open-label pravas- 
tatin (or placebo, depending on original treatment 
assignment). If these measures are unsuccessful, the 
patient is withdrawn from the study. 
Evaluatii of patients: Patients are to return to the 
clinic every 6 weeks for the first 18 months of the study 
for safety evaluation (liver-enzyme elevation and ad- 
verse events), and every 12 weeks thereafter. Follow-up 
arteriography is to be performed after 36 months, or ear- 
lier, if feasible, in the event of withdrawal from the 
study, or coronary artery bypass graft surgery. As each 
patient completes the study, the paired baseline and fol- 
low-up cineangiograms (blinded to order and patient 
identifcation) will be reviewed by an experienced an- 
giographer who will select matching views for analysis. 
(The preliminary core laboratory reading will be used 
only for qualification of the Iilm.) 
Interim monhing/polii advkwy bozd The con- 
duct of the study is reviewed semiannually by a policy 
advisory board of 5 members (see Appendix) who are 
independent of the sponsor and trial organization. . . tmmh&ms/end point adysis plans: 
Original sample-size calculations were based on the lim- 
ited data then available on progression rates and vari- 
ability from the Coronary Artery Surgery Study.4 A to- 
tal sample size of 400 subjects was deemed adequate to 
demonstrate a 40% treatment effect. More recent quan- 
titative data enable more accurate sample-size esti- 
mates5 Assuming a decrease in mean coronary artery 
diameter of 0.20 mm in the placebo group, an SD of 
0.34 mm, 80% power and 0.05 significance level (Zsid- 
ed), the detectable treatment effect ranges between 51 
and 55% for 350 and 300 patients, respectively, com- 
pleting the study (allowing for withdrawals). 
The primary end point of the study is the rate of pro- 
gression for mean diameter averaged over the following 
10 segments: left main, proximal and mid-left anterior 
descending, largest diagonal, proximal and distal left cir- 
cumllex, largest obtuse marginal, and proximal, mid- 
and distal right. Any angiogram obtained 290 days after 
initiation of double-blind therapy can be included in the 
analysis of the primary end point. The primary analysis 
will be by intention-to-treat. Rates of progression will 
by analyzed using rank-based tests (e.g., rank-sum tests) 
and expressed as a slope (mm/month). (This results in 
the variable being weighted for time on trial.) If a fmal 
angiogram is not available in a subject because of death 
or myocardial infarction, a value will be imputed for that 
patient equal to the greatest progression rate observed in 
the group completing 36 months in the trial, corrected 
for duration of follow-up. Arteries and segments that 
undergo angioplasty or coronary artery bypass graft will 
be excluded from the study. (Patients undergoing coro- 
nary artery surgery during the study will be delined as 
having reached a study end point, and the angiogram be- 
fore surgery will be included in the analysis.) 
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Several secondary angiographic and lipoprotein end 
point analyses are planned (Table II). Secondary clinical 
end points include occurrence of myocardial infarction, 
stroke, angioplasty and coronary artery bypass graft 
surgery, and total and cause-specific mortality. 
RESULTS 
Recruitment began in early 1988 and ended approxi- 
mately 2.5 years later (Figure 1). Tables III and IV list 
the reasons why patients were excluded during the 
screening and dietary lead-in periods. The most frequent 
reason for excluding a patient during the early screening 
phase was low serum cholesterol level. In general, sub- 
jects were enrolled in the dietary stabilization phase if 
the screening total cholesterol level was 2210 to 220 
mg/dl, although there was considerable variation from 
site to site, and the threshold depended on whether a fat- 
restricted diet was already being followed. Based on the 
accumulating experience, several changes were made in 
the protocol and conduct of the study (including increas- 
TABLE II Secondary End Points 
Angiographic measurements 
Mean minimal diameter 
Mean maximal diameter 
Mean percent stenosis 
Development of new lesions 
Change in average severity of lesions 
Average no. of lesions and new lesionsipt. 
Lesion changes stratified by baseline severity 
Incidence of progression, regression and mixed progression/regression, 
or no change 
Lipoprotein and apolipoproteins 
Total and low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, high-density lipoproteinz, and high-density lipoproteins 
Triglycerides 
Apolipoproteins A-l and I3 
Lipoprotein (a) 
FlBUBE 1. Patient recruit- 
ment. mw indicetes when 
pmtocol wee modlled to in- 
clude patients with lowdew 
sity lipoprotein cholesterol 
2130 mg/dl. 
ing the number of participating centers) to enable ran- 
domization to be completed successfully. The protocol 
revision having the greatest impact on enrollment was 
changing the lower limit required for mean LDL choles- 
terol from 150 to 130 mg/dl (Figure 1). This fmding pro- 
vides additional support for the qualitative observation 
that most patients with coronary artery disease have only 
moderate increases of total and LDL cholesterol. 
Other revisions with only modest effects on recruit- 
ment included increasing the upper age limit from 70 to 
75 years, and the upper limit for triglycerides from 300 
to 350 mg/dl, and allowing subjects with stable or un- 
TABLE Ill Patients Excluded After Screening 
Patients screened 
Patients excluded 
Screening total cholesterol too low 
Too ill 
Normal coronary arterres 
Diabetes mellitus 
Age 
Concomitant illnesses or prohibited medications 
Angiography protocol not followed 
No qualifying clinical or angiographic criteria 
Refused to participate 
Other/not specified 













TABLE IV Reasons for Disqualification in Patients Enrolled But 
Not Randomized 
Patients enrolled 1,114 
Patients excluded 706 
Low-density lipoprotein cholesterol concentration too low 240 
Triglyceride concentration too high 25 
Patient withdrew 166 
Angiogram rejected 54 










- -TOTAL # RANDOMIZED 
AMJJASONDJFMAMJJASONDJFMAMJJA 
MONTH (1988-90) 
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TABLE V Reasons for Rejection of Baseline Angiograms by 
Core Angiography Laboratory 
Excessive streaming 24 
Excessive editing 22 
No qualifying lesion 15 
Absent or inadequate views 9 
3-vessel bypass 8 
Nitroglycerin not given 5 
Inadequate documentation 4 
Automated catheter tracking not possible 1 
Angioplasty urgently needed 1 
Total films rejected 89 
Total films screened 895 
stable angina (in addition to those after myocardial in- 
farction or angioplasty) to participate in the study. 
Tables IlI and IV show that some patients were ex- 
cluded from the study because either the angiographic 
protocol was not followed, or qualifying clinical or angi- 
ographic criteria were absent, or both. Some patients 
were included whose angiograms were sent for certifica- 
tion, but were not accepted after analysis in the core 
angiography laboratory. Table V shows the reasons for 
rejecting these films. The overall acceptance rate was 
90.1% of submitted films. In contrast, in the early phas- 
es of the study, the acceptance rate was as low as 71%. 
Protocol adherence and film quality improved after the 
reasons for rejection were reviewed with the clinical 
sites. 
Baseline demographic characteristics of the 408 pa- 
tients randomized are listed in Table VI. 
DISCUSSION 
PLAC I and other ongoing studies should help es- 
tablish whether treatment of patients with moderately 
increased serum cholesterol levels slows progression of 
coronary artery disease and presumably prevents clini- 
cal events as much as in trials of those with severe hy- 
percholesterolemia. 6,7 The positive or negative results 
should have important implications for the large num- 
ber of patients with coronary artery disease but only 
moderate LDL cholesterol elevation. 
Several features of the design and recruitment of pa- 
tients in the trial deserve comment, and may bear on the 
design of future studies. Assessment of the progression 
of coronary artery disease was the primary aim. Thus, 
before randomization, each patient’s angiogram was 
screened through the core angiography laboratory to 
ensure that the protocol was followed and that the 
angiogram could be sufficiently digitized to ensure ade- 
quate analysis at the end of 3-year follow-up. In the 
early phases of the study, >lOO angiographers were par- 
ticipating, and variation in attention to contrast stream- 
ing and protocol adherence was considerable. After core 
laboratory personnel rejected several lihns, protocol 
adherence improved substantially. Table V documents 
the value of using this approach in conjunction with 
quantitative angiography to ensure adequacy of baseline 
films. 
The most frequent reason for excluding patients from 
the study was low serum cholesterol (Table BI). A large 
proportion of patients with documented coronary artery 
disease have cholesterol concentrations only modestly 
TABLE VI Baseline Demographic Characteristics 
Group A Group B 
Mean age (years) 57 57 
Range 37-75 33-72 
Men/women (%) 76124 79121 
Race (%) 
White 90 86 
Other 10 14 
Average total cholesterol (mg/dl) 229 232 
Range* 172-294 175-294 
Average low-density lipoprotein cholesterol 162 165 
(mg/dl) 
Range* 119-220 113-208 
Average high-density lipoprotein cholesterol 41 41 
(mgidl) 
Range* 23-98 25-70 
Average triglycerides (mg/dl) 165 167 
Range* 49-511 46425 
*Last observation before randomization. 
increased or within the range considered normal for the 
U.S. population. The data support conclusions from 
other studies8,9 and have important implications not only 
for future trials but also for understanding the patho- 
genesis of coronary artery disease. Mechanisms other 
than hyperlipidemia, such as insulin resistance, may be 
of substantial pathophysiologic importance in patients 
with only moderate or no increase in serum LDL choles- 
terol. Although a lipid-lowering strategy such as mono- 
therapy with pravastatin is likely to benefit patients with 
severe or moderately severe hypercholesterolemia, the 
effect of reducing lipids in those with only minimal or 
no increase in serum lipids despite coronary artery dis- 
ease should be determined. 
APPENDIX 
Study organization: PARTICIPATWGWSTI~TIONSAND 
PREWIPAL INVESTIGATORS: University of Michigan Hos- 
pital, Ann Arbor, MI: Bertram Pitt, MD, Stephen G. 
Ellis, MD; Henry Ford Hospital, Detroit, MI: Howard 
S. Rosman, MD; Sinai Hospital, Detroit, MI: Melvyn 
Rubenfire, MD; William Beaumont Hospital, Royal 
Oak, MI: Gerald C. Timmis, MD; Saint Joseph Hospi- 
tal, Ann Arbor, MI: Ronald Van den Belt, MD; Dea- 
coness Hospital, St. Louis, MO: Harold L. Kennedy, 
MD; Georgetown University Medical Center, Washing- 
ton, D.C.: Charles E. Rackley, MD, Burns Clinical Re- 
search Foundation, Petoskey, MI: Harry T, Colfer, MD, 
Johns Hopkins University, Baltimore, MD: Lewis C. 
Becker, MD; Humana Heart Institute, Louisville, KY: 
David A. Dageforde, MD; Central Ohio Znterven- 
tionists, Columbus, OH: Richard J. Candela, MD; New 
Mexico Heart Clinic, Albuquerque, NM: George F. 
Leatherman, MD; Washington Adventist Hospital, Ta- 
coma Park, MD: Robert DiBianco, MD; and Core An- 
giography Laboratory University Hospital, University 
of British Columbia, Vancouver, British Columbia, 
Canada: G. B. John Mancini, MD, Director. 
POLICY ADVISORY BOARD: W; Virgil Brown, MD, 
Emory University, Atlanta, GA; Harold T. Dodge, MD, 
University of Washington, Seattle, WA;Richard A. Kron- 
mal, PhD, University of Washington, Seattle, WA; 
Albert Oberman, MD, University of Alabama, Birming- 
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ham, AL; and Jeffrey Raines, PN>, University of Miami, 
Miami, FL. 
CENTRAL LIPID ANALYTIC LABORATORY: Lipid Research 
Center, Washington University School of Medicine, St. 
Louis, MO: Thomas G. Cole, PhD, Director. 
CENTRAL APOLIPOPROTEIN ANALYTIC LABORATORY: 
Center for Cardiovascular Research, Sinai Hospital of 
Detroit, Detroit, MI: James J. Maciejko, PhD, Director. 
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